Verdad Advisers’s Rhythm Pharmaceuticals RYTM Stock Holding History

Verdad Advisers’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,445	Closed	-$213K	–	263
2026 Q1	$213K	Buy	+2,445	New	+$238K	0.24%	128

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Verdad Advisers's RYTM Position: Q2 2026 in Review

Verdad Advisers sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2026, closing a stake of 2,445 shares — an estimated $213K sold.

Verdad Advisers first reported a position in RYTM in Q1 2026 and held it in 1 quarter. The position peaked at $213K in Q1 2026. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

Verdad Advisers reported no remaining Rhythm Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Verdad Advisers sold 2,445 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $213K.
Verdad Advisers first reported a position in Rhythm Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Verdad Advisers's Rhythm Pharmaceuticals position peaked at $213K in Q1 2026.
303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.